Remove Drug Development Remove Leadership Remove Life Science
article thumbnail

Accenture Invests in QuantHealth to Accelerate Use of AI-Powered Clinical Trial Simulations to Drive Cost-Effective Drug Development

Healthcare IT Today

By simulating trials at scale, QuantHealth’s platform can lower risks, expedite, and optimize drug development. QuantHealth is already working with several global pharmaceutical companies to use its product in clinical trial design and development. Petra Jantzer, Ph.D., Originally announced January 8th, 2024

article thumbnail

Merative formerly IBM Watson Health poised to launch raft of new products in 2025

Lloyd Price

The new company aims to leverage its extensive data sets and technology to provide innovative solutions across various healthcare sectors, including life sciences, provider, imaging, health plan, employer, and government health and human services.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Healthcare AI Tools – 2025 Health IT Predictions

Healthcare IT Today

Chris McSpiritt, Head of Life Sciences at Domino Data Lab Next year will see AI-enhanced imaging technologies significantly improve diagnostic accuracy in radiology and pathology, empowering clinicians to make quicker and more reliable decisions at the point of care. Today, it’s largely restricted to genomics and oncology.

article thumbnail

Koneksa Announces Expanded Partnership with SSI Strategy to Scale the Adoption of Digital Biomarkers in Clinical Trials

Digital Health Global

As part of the partnership, SSI will expand Koneksa’s medical strategy division, especially in translational and clinical drug development. Koneksa clients gain access to a team of PhDs and MDs at SSI with expertise in drug development.

article thumbnail

Turbine Upsizes its Series A Round to €25.5 Million and Appoints Seasoned Independent Directors to its Board

Digital Health Global

These individuals have personally built leading technology platforms supercharging drug development globally. Their buy-in shows that our platform is differentiated and poised to unlock truly novel therapies for currently underserved patient populations through efficient, simulation-guided development. Jane Rhodes, Ph.D.,

BioTech 88
article thumbnail

Where are HealthTech's soft landing M&A deals in today's market?

Lloyd Price

AI and machine learning: Companies with advanced AI solutions for tasks like drug discovery, clinical trial optimisation, and personalised medicine can be attractive targets. Visit [link] HealthTech Corporate Development - Buy Side, Sell Side, Growth & Strategy services for Founders, Owners and Investors.

article thumbnail

Pharma – 2025 Health IT Predictions

Healthcare IT Today

AI capabilities will become a critical differentiator, with companies that successfully implement AI solutions gaining significant advantages in drug discovery and development speed, cost reduction, and market intelligence. It’s not just a trend, but a reality we fully expect will accelerate in the coming year.